Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.
Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.
Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.
Kite and Arcellx have announced a global collaboration to co-develop the CART-ddBCMA therapy for relapsed or refractory multiple myeloma. Kite will provide an upfront payment of $225 million and a $100 million equity investment. The companies will share development and commercialization costs, splitting U.S. profits 50/50. The partnership aims to address the significant unmet need in multiple myeloma treatment.
The transaction is expected to close in Q1 2023 and may reduce Gilead's EPS by approximately $0.16. The collaboration capitalizes on Kite's leadership in cell therapy and Arcellx's innovative approach.
Arcellx and Kite, a Gilead Company, have entered into a strategic collaboration to co-develop and commercialize CART-ddBCMA, a late-stage cell therapy for relapsed or refractory multiple myeloma. Arcellx will receive an upfront payment of $225M, a $100M equity investment, and potential contingent payments up to $3.9B. The companies will share U.S. profits 50/50 while Arcellx earns royalties on sales outside the U.S. The collaboration aims to accelerate patient access to innovative therapies.
ImmunoGen (Nasdaq: IMGN) has announced a clinical collaboration with Gilead Sciences (Nasdaq: GILD) to investigate the safety and anti-leukemia activity of pivekimab sunirine combined with magrolimab in patients with relapsed CD123-positive acute myeloid leukemia (AML). This partnership aims to explore the complementary mechanisms of action of both drugs. The new cohort, part of ImmunoGen's ongoing 802 study, will evaluate up to 42 patients with a focus on the complete response rate. Pivekimab is being developed for various hematologic malignancies and has received critical designations from regulatory bodies.
Marcus, a 36-year-old military veteran, was diagnosed with diffuse large B-cell lymphoma after noticing unusual growths. Although he achieved remission following six rounds of chemotherapy, the cancer returned aggressively, affecting his trigeminal nerve.
He was then referred to the University of Maryland Greenebaum Comprehensive Cancer Center, where he received CAR T-cell therapy. The initial PET CT scan revealed a dramatic response to the treatment. Grateful for the opportunity to spend precious time with his son, Marcus emphasized the importance of life and family.
Kite Pharma, a Gilead Company, and Daiichi Sankyo announced the transfer of marketing authorization for Yescarta (axicabtagene ciloleucel) in Japan to Gilead Sciences K.K. This follows a revision of their 2017 partnership agreement. Kite will manage sales and promotion activities in Japan post-transfer. The manufacturing facility in California is authorized to produce Yescarta for the Japanese market, with supply expected to start in early 2023. Currently, there are six hospitals in Japan approved to provide this CAR T-cell therapy.
Gilead Sciences (GILD) announced new data from the TROPiCS-02 Phase 3 study of Trodelvy (sacituzumab govitecan-hziy) showing improved efficacy in HR+/HER2- metastatic breast cancer patients. Trodelvy outperformed standard chemotherapy, enhancing progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) across varying Trop-2 expression levels. The FDA has accepted a priority review for Trodelvy in this indication, with a decision expected by February 2023.
Gilead Sciences (GILD) announced the European Commission's authorization of a new low-dose tablet form of Biktarvy for HIV treatment in virologically suppressed children aged two years and older, weighing at least 14 kg. This marks the first pediatric approval for Biktarvy in the EU, addressing a significant unmet need for HIV treatment in children. The decision is based on positive results from a clinical study, showing high rates of virological suppression among participants. Biktarvy combines three antiretroviral drugs into a single tablet and is indicated for use without prior evidence of viral resistance.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced positive results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line metastatic non-small cell lung cancer (NSCLC). The analysis, conducted with a data cutoff on August 31, 2022, included 150 patients and demonstrated that both domvanalimab combinations significantly outperformed zimberelimab monotherapy across multiple efficacy measures, including progression-free survival (PFS). Results will be presented at the ASCO Monthly Plenary Series on December 20, 2022.
Gilead Sciences and Arcus Biosciences announced promising results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line NSCLC patients. The study evaluates the effects of domvanalimab (anti-TIGIT) in combination with zimberelimab (anti-PD-1) versus zimberelimab alone. Results indicate significant clinical benefits across key efficacy measures, including progression-free survival (PFS). No unexpected safety issues were noted. Full results will be presented on December 20, 2022, at the ASCO Monthly Plenary Series.
Gilead Sciences (Nasdaq: GILD) will present at key investor conferences including the Evercore ISI Annual HealthCONx Conference on November 29 at 1:00 PM ET, and the Piper Sandler Healthcare Conference on November 30 at 11:30 AM ET. Additionally, the Nasdaq Investor Conference is scheduled for December 7 at 1:00 PM GMT. Live webcasts can be accessed at investors.gilead.com, with replays available for 30 days.
Gilead has over three decades of experience in biopharmaceutical innovation, focusing on treatments for HIV, hepatitis, and cancer.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
What is Gilead Sciences, Inc.?
Where is Gilead Sciences headquartered?
What are some key products of Gilead Sciences?
Which companies has Gilead Sciences acquired?
What diseases does Gilead Sciences' portfolio cover?
How has Gilead expanded its oncology offerings?
What is Gilead's financial condition?
What is Gilead's approach to research and development?
What recent projects is Gilead working on?
Where can I find the latest news about Gilead Sciences?
